Common Questions

What is the difference between Zaire Ebola and Bundibugyo Ebola?

Zaire ebolavirus has a case-fatality rate of 50-90% untreated and has caused the largest outbreaks including the 2014-16 West Africa epidemic. Bundibugyo has a lower CFR of 30-40% and has caused only three outbreaks before 2026, including the current Ituri PHEIC. Critically, Zaire has three licensed medical countermeasures (Ervebo, Inmazeb, Ebanga) while Bundibugyo has none.Source: WHO; FDA; PALM trial

Why does Zaire Ebola have a vaccine but Bundibugyo does not?

Zaire ebolavirus caused the 2014-16 West Africa epidemic of 28,000 cases, which created both the scientific imperative and the clinical trial opportunity to develop Ervebo, Inmazeb and Ebanga. Bundibugyo caused three small outbreaks with a total case count insufficient to power a randomised clinical trial; the WHO R&D Blueprint named the Bundibugyo MCM gap only in Q1 2026, three months before the first PHEIC.Source: WHO R&D Blueprint Q1 2026; FDA labels

What happened in the 2014-16 West Africa Ebola outbreak?

The 2014-16 West Africa Ebola outbreak was caused by Zaire ebolavirus and produced 28,616 cases and 11,310 deaths across Guinea, Sierra Leone and Liberia — the largest outbreak in the history of the disease. It drove the development of Ervebo, which was authorised under emergency protocols in 2016 and received full FDA approval in 2019. Inmazeb and Ebanga emerged from the follow-on 2018-20 Kivu outbreak in DRC.Source: WHO; CDC

Background

Zaire ebolavirus (EBOV) is the Ebola species responsible for the highest-mortality and highest-profile outbreaks in the genus's recorded history. First identified at Yambuku, DRC, in 1976, it caused the 1995 Kikwit outbreak (315 cases, 81% CFR), the 2014-16 West Africa epidemic (28,000 cases, 11,000 deaths — the largest Ebola outbreak on record), and the 2018-20 Kivu outbreak in eastern DRC (3,481 cases, 2,299 deaths). Case-fatality rates in healthcare settings average 50-90% in untreated patients; rates fell significantly with the introduction of Inmazeb and Ebanga following the PALM trial.

Zaire ebolavirus is the only Ebola species for which licensed vaccines and monoclonal antibody therapies exist. The VSV-ZEBOV vaccine (brand name Ervebo, developed by Merck) was used in ring vaccination during the 2018-20 Kivu outbreak and licensed by the FDA in 2019. Inmazeb (Regeneron) and Ebanga (Ridgeback Biotherapeutics) were both approved in 2020 following the PALM trial. All three are species-specific: they target the Zaire glycoprotein, which is sufficiently different from the Bundibugyo, Sudan, Reston, Tai Forest and Bombali glycoproteins that cross-species efficacy cannot be assumed.

The clinical contrast between Zaire ebolavirus and Bundibugyo ebolavirus defines the core medical-countermeasures paradox of the 2026 PHEIC: for Zaire, the global health system developed and deployed tools in an eight-year period from 2011 to 2020 that reduced treatment mortality to under 12% for patients with low viral loads. For Bundibugyo, which has caused three outbreaks in 18 years with a total case count that never previously triggered a PHEIC, the development imperative was absent — and the 2026 Ituri outbreak finds clinical teams with the same toolkit as 1976.

Source Material

About Ebola — CDC

How the World Sees Them

DRC communities

Zaire ebolavirus killed hundreds of thousands in DRC and West Africa; the investment that produced Ervebo, Inmazeb and Ebanga was driven by outbreak scale and media attention that Bundibugyo never generated.

Pharmaceutical companies

Ervebo, Inmazeb and Ebanga are commercially viable products in the sense that they have FDA/EMA approvals and can be stockpiled for humanitarian deployment; no company has initiated equivalent Bundibugyo development.

Global health R&D community

Zaire's repeated large outbreaks created the clinical trial opportunity and commercial incentive that drove MCM development; Bundibugyo's three small outbreaks before 2026 were insufficient to sustain a development pipeline.